MGTX
MeiraGTx Holdings plc
stockNASDAQ
meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer's disease (ad), parkinson's disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 11.11 | 2026-09-28 | -2.83% | 1.598 |
| 1M | 13.89 | 2026-09-04 | -22.28% | 0.864 |
| 3M | 13.89 | 2026-07-06 | -22.28% | 0.699 |
| 6M | 9.52 | 2026-04-06 | +13.39% | 1.284 |
| 1Y | 8.41 | 2025-10-06 | +28.36% | 1.604 |
| 2Y | 4.15 | 2024-10-04 | +160.12% | — |
| 5Y | 12.78 | 2021-10-05 | -15.53% | 1.234 |
MeiraGTx Holdings plc (NASDAQ:MGTX) stock price today is $10.80, and today's volume is 820,038. MGTX is up 1.266% today. The 30 day average volume is 911,157. MGTX market cap is $1.04B with 96.04M shares outstanding.